<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335543</url>
  </required_header>
  <id_info>
    <org_study_id>IAGTDK-70-3046-Ho2</org_study_id>
    <secondary_id>CDR0000472206</secondary_id>
    <secondary_id>EU-20609</secondary_id>
    <secondary_id>ISRCTN78805636</secondary_id>
    <nct_id>NCT00335543</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Preoperative Chemoradiation in Locally Resectable Adenocarcinoma of Pancreatic Head Without Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy&#xD;
      together with radiation therapy before surgery may make the tumor smaller and reduce the&#xD;
      amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill&#xD;
      any tumor cells that remain after surgery. It is not yet know whether giving chemotherapy&#xD;
      together with radiation therapy before surgery is more effective than surgery alone in&#xD;
      treating pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving gemcitabine and cisplatin&#xD;
      together with radiation therapy before surgery works compared to surgery alone in treating&#xD;
      patients with localized pancreatic cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether neoadjuvant chemoradiotherapy comprising gemcitabine hydrochloride,&#xD;
           cisplatin, and radiotherapy is better than immediate surgery, in terms of median&#xD;
           survival, in patients with locally resectable adenocarcinoma of the pancreatic head.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare 3-year survival rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare R0 resection rate in these patients.&#xD;
&#xD;
        -  Compare the rate of medium and high toxicity events in these patients.&#xD;
&#xD;
        -  Compare the rate of complete and incomplete remission of the tumor as measured by&#xD;
           radiographic imaging studies.&#xD;
&#xD;
        -  Compare the rate of different regression gradings in resected tumor specimens.&#xD;
&#xD;
        -  Compare the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective, randomized, controlled, open-label, multicenter study.&#xD;
      Patients are stratified according to participating center and staging laparoscopy (yes vs&#xD;
      no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV&#xD;
           over 1 hour on days 1, 8, 22, and 29. Patients also undergo radiotherapy to the tumor&#xD;
           and surrounding lymph nodes 5 days a week for 5 weeks followed by 3 more doses of&#xD;
           radiotherapy directly to the tumor. Approximately 6 weeks after finishing&#xD;
           chemoradiotherapy, patients with no evidence of disease progression undergo surgery to&#xD;
           remove the tumor.&#xD;
&#xD;
        -  Arm II: Patients undergo surgery to remove the tumor. After surgery, all patients&#xD;
           receive adjuvant chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes on&#xD;
           days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, at the end of chemotherapy and before surgery (arm&#xD;
      I), and then at 6 weeks, 6 months, 12 months, and 24 months after surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years and&#xD;
      then at 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 254 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year survival rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medium and high toxicity events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete and incomplete remission of the tumor as measured by radiographic imaging studies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of different regression gradings in resected tumor specimens</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before, during, and after therapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreatic head&#xD;
&#xD;
               -  No tumors of the body or tail, as defined by a tumor lying between the left&#xD;
                  border of the superior mesenteric vein and the left border of the aorta and/or&#xD;
                  the left border of the aorta and the hilum of the spleen&#xD;
&#xD;
          -  Locally resectable disease by CT scan&#xD;
&#xD;
               -  Major vessels (e.g., portal vein, confluence of mesenteric and splenic vein,&#xD;
                  superior mesenteric artery, celiac trunk, splenic artery, hepatic artery, or&#xD;
                  superior mesenteric vein) maximally enclosed ≤ 180° by the tumor&#xD;
&#xD;
          -  No infiltration of extrapancreatic organs except the duodenum&#xD;
&#xD;
          -  No carcinoma of the ampulla of Vater&#xD;
&#xD;
          -  No metastasis&#xD;
&#xD;
          -  No peritoneal carcinoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Creatinine clearance &gt; 70 mL/min&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  No liver cirrhosis&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No respiratory insufficiency&#xD;
&#xD;
          -  No grade III or IV cardiac arrhythmias&#xD;
&#xD;
          -  No pathology on EKG&#xD;
&#xD;
          -  No other severe cardiopulmonary disease&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  No other disease that renders the patient unsuitable for one treatment option&#xD;
&#xD;
          -  No other malignancy except nonmelanoma skin cancer, carcinoma in situ of the cervix,&#xD;
             or other cancer for which the patient was treated with surgery only and has been in&#xD;
             complete remission for ≥ 10 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 3 months since prior participation in another clinical trial&#xD;
&#xD;
          -  No prior or other concurrent treatment for carcinoma of the pancreas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Hohenberger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaet Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaft Krankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>D-28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden - Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>D-01008</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arbeitsgruppe Lebermetastasen und Tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik am Eichert</name>
      <address>
        <city>Goeppingen</city>
        <zip>D-73035</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Universitaetsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Nord</name>
      <address>
        <city>Nuremberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, Meyer T. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008 Jul;34(7):756-64. doi: 10.1016/j.ejso.2007.11.012. Epub 2008 Jan 10.</citation>
    <PMID>18191528</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

